# US 2026/0061053 A1 · Cd19-directed chimeric antigen receptor cell therapy for treating autoimmune and neurological diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061053 A1
- Document ID: US20260061053A1
- Status: Published application
- Kind: A1
- Application number: 19/312,063
- Filed: 2025-08-27
- Published: 2026-03-05
- Earliest claimed: 2024-08-28
- Assignees: Juno Therapeutics, Inc.
- Applicants: Juno Therapeutics, Inc.
- Inventors: Ashley KOEGEL; Timothy CAMPBELL; Tyler Jordan KOOP; Renee Ann Sehee RANDAZZO; Alexis MELTON; Burhan Zafar CHAUDHRY; Nivedita GULATI
- Web page: https://patentgrep.com/patent/US20260061053A1

## CPC

- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 40/4211: {CD19 or B4}
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 21/04: for myasthenia gravis
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 2317/622: Single chain antibody (scFv)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are adoptive cell therapy methods and uses involving the administration of a dose of T cells expressing a CD19-directed chimeric antigen receptor for treating subjects with autoimmune and neurological disease and disorders and related methods, compositions, uses and articles of manufacture.

## Claims

### Claim 1

A method of treating a subject, the method comprising administering a dose of CD19-directed genetically modified T cells to a subject, wherein the T cells of the dose are positive for expression of a chimeric antigen receptor (CAR) that binds CD19 and the dose is from 1×106 to 50×106 CAR-positive T cells, wherein the subject is a subject:
(i) having or suspected of having Myasthenia gravis (MG) and has severe disease that is refractory to three or more prior therapies for treating MG;
(ii) having or suspected of having primary Sjogren's Disease (SiD), wherein the subject is characterized with refractory disease that is refractory to at least one prior therapy for treating SjD and/or with extraglandular disease;
(iii) having or suspected of having ANCA-associated vasculitis (AAV);
(iv) having or suspected of having Rheumatoid Arthritis (RA), wherein the subject has severe disease that is refractory to three or more prior therapies for treating RA;
(v) having or suspected of having Autoimmune Encephalitis (AE);
(vi) having or suspected of having Pemphigus:
(vii) having or suspected of having Membranous Nephropathy (MN);
(viii) having or suspected of having Immunoglobulin G4-related disease (IgG4-RD);
(ix) having or suspected of having Neuromvelitis optica spectrum disorder (NMOSD);
(x) having or suspected of having Stiff-person syndrome (SPS);
(xi) having or suspected of having Irritable bowel disease (IBD);
(xii) having or suspected of having Thrombotic Thrombocytopenia Purpura (TTP);
(xiii) having or suspected of having Autoimmune hemolytic anemia (AIHA);
(xiv) having or suspected of having Immune thrombocytopenia (ITP);
(xv) having or suspected of having chronic Immune thrombocytopenia (cITP);
(xvi) having or suspected of having IgA nephropathy;
(xvii) having or suspected of having bullous pemphigoid (BP); or
(xviii) having or suspected of having ulcerative colitis (UC).

### Claim 2

A method for reducing disease activity, the method comprising administering a dose of CD19-directed genetically modified T cells to a subject, wherein the T cells of the dose are positive for expression of a chimeric antigen receptor (CAR) that binds CD19 and the dose is from 1×106 to 50×106 CAR-positive T cells, and the subject is a subject:
(i) having or suspected of having Myasthenia gravis (MG), wherein the subject has severe disease that is refractory to three or more prior therapies for treating MG,
(ii) having or suspected of having primary Sjogren's Disease (SjD), wherein the subject is characterized with refractory disease that is refractory to at least one prior therapy for treating SjD and/or with extraglandular disease:
(iii) having or suspected of having ANCA-associated vasculitis (AAV);
(iv) having or suspected of having Rheumatoid Arthritis (RA), wherein the subject has severe disease that is refractory to three or more prior therapies for treating RA:
(v) having or suspected of having Autoimmune Encephalitis (AE):
(vi) having or suspected of having Pemphigus:
(vii) having or suspected of having Membranous Nephropathy (MN);
(viii) having or suspected of having Immunoglobulin G4-related disease (IgG4-RD):
(ix) having or suspected of having Neuromyelitis optica spectrum disorder (NMOSD);
(x) having or suspected of having Stiff-person syndrome (SPS);
(xi) having or suspected of having Irritable bowel disease (IBD):
(xii) having or suspected of having Thrombotic Thrombocytopenia Purpura (TTP),
(xiii) having or suspected of having Autoimmune hemolytic anemia (AIHA):
(xiv) having or suspected of having Immune thrombocytopenia (ITP);
(xv) having or suspected of having chronic Immune thrombocytopenia (cITP);
(xvi) having or suspected of having IgA nephropathy;
(xvii) having or suspected of having bullous pemphigoid (BP); or
(xviii) having or suspected of having ulcerative colitis (UC).

### Claim at position 3

3-19. (canceled)

### Claim 20 (depends on 1)

The method of claim 1, wherein the subject has relapsed following remission after treatment with a prior therapy.

### Claim at position 5

21-24. (canceled)

### Claim 25

A method for post-induction maintenance therapy for treating ANCA-associated vasculitis (AAV) or Autoimmune Encephalitis (AE),
the method comprising administering a dose of CD19-directed genetically modified T cells to a subject having received an induction therapy for treating ANCA-associated vasculitis (AAV) or AE, respectively, wherein the T cells of the dose are positive for expression of a chimeric antigen receptor (CAR) that binds CD19 and the dose is from 1×106 to 50×106 CAR-positive.

### Claim at position 7

26-37. (canceled)

### Claim 38 (depends on 1)

The method of claim 1, wherein the subject has severe disease that is refractory to one or more prior therapies.

### Claim 39 (depends on 38)

The method of claim 38, wherein the one or more prior therapy is two or more prior therapies.

### Claim at position 10

-75. (canceled)

### Claim 76 (depends on 1)

The method of claim 1, wherein the subject has a relapsed or refractory disease to one or more prior therapies for treating the disease.

### Claim 77 (depends on 76)

The method of claim 76, wherein the one or more prior therapies are two or more prior therapies for treating the disease.

### Claim 78 (depends on 76)

The method of claim 76, wherein at least one of the one or more prior therapies is an anti-CD20 antibody.

### Claim 79 (depends on 76)

The method of claim 76, wherein the subject has a severe disease.

### Claim at position 15

80-85. (canceled)

### Claim 86 (depends on 1)

The method of claim 1, wherein the T cells are autologous to the subject.

### Claim 87 (depends on 1)

The method of claim 1, further comprising obtaining a leukapheresis sample from the subject for manufacturing the composition comprising engineered T cells.

### Claim 88 (depends on 1)

The method of claim 1, wherein prior to the administration, the subject has been preconditioned with a lymphodepleting therapy.

### Claim 89 (depends on 1)

The method of claim 1, wherein the method further comprises, immediately prior to the administration of the dose of CD19-directed genetically modified T cells, administering a lymphodepleting therapy to the subject, wherein the lymphodepleting therapy comprises the administration of fludarabine and/or cyclophosphamide.

### Claim at position 20

90-114. (canceled)

### Claim 115 (depends on 1)

The method of claim 1, wherein the dose of T cells comprises CD4+ T cells expressing the CAR and CD8+ T cells expressing the CAR.

### Claim 116 (depends on 1)

The method of claim 1, wherein the dose of T cells comprises CD4m T cells expressing the CAR and CD8m T cells expressing the CAR at a ratio between about 1:5.

### Claim 117 (depends on 1)

The method of claim 1, wherein at least or at least about 90% of the T cells are CD3+ cells.

### Claim at position 24

118-120. (canceled)

### Claim 121 (depends on 1)

The method of claim 1, wherein at least 80% of the T cells are viable T cells.

### Claim 122

(canceled)

### Claim 123 (depends on 1)

The method of claim 1, wherein the subject is human.
